Analyzing the MFS Growth Fund’s 2015 Portfolio
The information technology, consumer discretionary, and healthcare sectors form the core of the MFS Growth Fund.
Analysts’ Recommendations for Align Technology in August 2017
Of the 13 analysts covering Align Technology in August 2017, eight rated the company a “strong buy,” and five rated it a “buy.”
Glenview Capital opens new position in Danaher
Glenview Capital Management added a new position in Danaher Corp. (DHR) in the third quarter. The position accounted for 1.99% of the fund’s total portfolio.
Sterne Agee CRT Rated Ecolab as a ‘Buy’
Ecolab (ECL) reported fiscal 4Q15 net sales of $3,412.0 million—a fall of 7.3% compared to net sales of $3,680.8 million in fiscal 4Q14.
Must-know highlights of Citadel Advisors’ 2Q14 positions
Citadel Advisors’ 2Q14 portfolio was worth $73.4 billion, up from $72.5 billion in 1Q14. The total portfolio has over 3000 stocks.
What Wall Street Analysts Recommend for Dentsply Sirona
Dentsply Sirona (XRAY), one of the leading dental technology providers in the United States, recently outlined a turnaround plan to recover from the company’s disappointing performance in recent years.
Align Technology: Analysts Raise Their Target Prices
On May 25, Berenberg increased its 12-month target price on Align Technology (ALGN) from $312 to $340.
ALGN Stock Surpasses the S&P 500 Index’s Year-to-Date Gain
On September 28, Align Technology (ALGN) posted an ~74% increase year-to-date. In the same period, the S&P 500 Index has returned ~9%.
Why Did Dover Stock Fall after 1Q16 Earnings Release?
Dover (DOV), a diversified industrials (XLI) company, released its 1Q16 earnings before the Market opened on April 21, 2016. The stock reacted negatively to the company’s performance.
Danaher Corporation’s Excess Returns Fail to Impress
Earlier in this series, we looked at Danaher’s return on invested capital on a standalone basis. However, we were only looking at half the story.
Credit Suisse Raised Ecolab Price Target to $109 per Share
Ecolab (ECL) reported fiscal 4Q15 net sales of $3,412.0 million, a fall of 7.3% compared to net sales of $3,680.8 million in fiscal 4Q14.
Danaher’s Environmental Segment Is a Cut above the Rest
Danaher’s Environmental & Applied Solutions unit was responsible for 25% of the company’s sales in 2015.
Introducing Danaher: A Diversified Healthcare Company
Danaher is a diversified conglomerate with a market cap of ~$56 billion. Its customers are mostly professionals and organizations rather than retail consumers.
Danaher Stock Jumps as EPS Grows 22.5% on Margin Expansion
Danaher (DHR) reported adjusted EPS of $0.87, which beat consensus estimates by $0.05. In growth terms, the adjusted EPS was 22.5% YoY.
The Pall–Danaher Spread is Trading Like a Safe Deal
A company that has grown largely by acquisition, Danaher is buying Pall, which makes filtration and separation technologies used in life sciences and industrial uses.
Viking Global buys a new stake in Regeneron Pharmaceuticals
Viking Global Investors revealed a brand new position valued at around $315 million in Regeneron Pharmaceuticals (REGN) last quarter. The position accounts for 1.32% of Viking’s total portfolio.
How Does Verifone Compare to Its Peers?
Verifone Systems (PAY) has achieved a healthy PE (price-to-earnings) ratio of 107.07x.
Glenview Capital increases stake in Fidelity National Financial
Glenview Capital Management added to its position in Fidelity National Financial (FNF) in the third quarter. Currently, the position accounts for 1.70% of the fund’s total portfolio.
Why Danaher Is Relatively Immune from Growth Concerns in China
Organically, Danaher (DGR) has grown at a CAGR of roughly 10% in China over the last five years. Approximately 50% of the company’s revenues in China are derived from its Diagnostics segment.
Verifone Systems Expands in 3Q15
Verifone Systems (PAY), with a market cap of $3.38 billion, is a leader in providing payment terminals, global payment as a service, and commerce enablement solutions.
Raytheon’s Missile Systems Segment’s Financial Performance
Raytheon’s Missile Systems segment had good growth in 4Q14. For the quarter, the net sales were $1,719 million. The net sales were up 5% YoY.
Glenview Capital raises position in Endo International
Glenview Capital Management added to its position in Endo International Plc (ENDP) in the third quarter. Currently, the position accounts for 2.02% of the fund’s total portfolio.
Dover Fluids: A Brief Overview
Dover Corporation’s (DOV) Fluids businesses include the Pump Solutions Group (or PSG), which provides pumping solutions to several end markets.
Understanding Dover’s Cash Flow Performance Over Time
Dover Corporation’s earnings undergo significant swings in changing business cycles. The company’s total sales fell by 10.3% to $7 billion in 2015, mostly due to steep organic declines in the energy segment.
Why did Halvorsen’s Viking Global boost its position in Illumina?
Viking Global Investors significantly increased its position in Illumina (ILMN) last quarter. The position, which accounted for 0.88% of Viking’s total 4Q 2013 portfolio, is now the fund’s third largest position, at 5.53% of the 1Q 2014 portfolio.
Analysts Cut Their Targets for XRAY ahead of Its 1Q18 Results
Dentsply Sirona, one of the leading dental technology providers in the United States, will announce its 1Q18 earnings results on May 7.
Danaher to Declare Its First Earnings after Fortive Separation
Danaher Corporation (DHR), which became a diversified healthcare company after its restructuring actions, is slated to declare its 3Q16 earnings on October 20. The consensus Wall Street estimate is for Danaher to post adjusted EPS of $0.83 on sales of ~$4.1 billion.
How 3M Stock Trended after Its 3Q17 Earnings
In this pre-earnings series, we’ll look at 3M’s stock performance since its 3Q17 results. On October 24, 2017, 3M announced its 3Q17 earnings and gained 5.9%.
Analyzing the Performance of Danaher’s Dental Business
Danaher Corp.’s (DHR) enterprise value is $85.21 billion, and its enterprise-value-to-revenue ratio is 4.42.
Must-know: Why did firms report a sharp spike in wages in May?
Manufacturing growth appears to be steady in the Fifth District. Although new orders declined sharply month-on-month, firms remained upbeat for business prospects.
GE Stock Upgraded by UBS with a ‘Buy,’ $14 Price Target
Markus Mittermaier, a new analyst at UBS, gave GE stock a “buy” rating yesterday. Previously, UBS offered a “neutral” rating on the stock.
Will the New GE CFO Achieve Larry Culp’s Goals?
Today, GE announced that Carolina Dybeck Happe will take charge as chief financial officer or CFO at GE, replacing from Jamie Miller early next year.
Could Earnings and Culp Continue to Boost GE Stock?
The third quarter was tough for multinational conglomerate General Electric (GE). Between July 1 and September 30, GE stock lost 15% of its value.
Why do key purchasing managers’ index readings move markets?
In this series, we’ll focus on the manufacturing PMI issued by three major institutions, measuring manufacturing activity in the U.S.
GE Stock Gains, Citigroup Sees Meaningful Turnaround
On Wednesday, General Electric (GE) stock rose 5.6% after a top Wall Street analyst made some positive remarks about its turnaround efforts.
Align Technology Stock Recovers after Tanking Last Week
Align Technology stock (ALGN) took a massive hit after Q2 earnings. So what was behind the massive decline, and what’s helping the stock recover?
Could GE’s Q2 Results Surprise Investors Again?
General Electric (GE) is slated to report its Q2 results on Wednesday. Let’s look at what analysts expect from the company in the second quarter.
BioPharma Sale to Strengthen General Electric’s Balance Sheet
In late February, General Electric (GE) made a breakthrough toward reducing its debt obligation and strengthening its balance sheet.
GE Wraps Up Q1 with a 37% Gain in Its Stock Price
Shares of GE have been surging since the beginning of the year and have probably seen the highest gain ever in a first quarter.
Why General Electric Stock Plunged ~7% Last Week
Larry Culp’s latest forecasts for GE’s industrial free cash flow have disappointed GE investors significantly.
GE Fell ~8% after J.P. Morgan Warned of More Downside Risk
GE stock extended its declines for the second consecutive day after a JPMorgan Chase analyst warned of more downside risk to the stock.
GE Soared after Larry Culp Stresses Debt Cut and Dividend Boost
General Electric (GE) was trading 1.4% higher in pre-market trading today after CEO Larry Culp reassured investors the company would return to a “position of strength.”
GE Shares Rose 2.5%, Analysts Turned Bullish on the Stock
On February 26, General Electric (GE) shares rose after several analysts provided positive comments about its recent deal.
Buffett Missing in Action as GE’s Turnaround Plan Gets Upvote
General Electric (GE) is up 9.1% today as of 11:50 AM ET. GE has announced that that it has entered a definitive agreement to sell its Biopharma business to Danaher (DHR).
Year-Long GE Transportation-Wabtec Merger Completed
General Electric (GE) closed the year-long pending merger of its Transportation business unit with Wabtec today.
GE Stock Rises on Announcement of BioPharma Unit Sale to Danaher
General Electric (GE) revealed today that it has entered a definitive agreement to sell its BioPharma business to Danaher.
Analysts Remain Bullish on Illumina Stock
In November, of the 19 analysts covering Illumina (ILMN), 14 have given it “buy” or higher ratings, and five have given it “hold” ratings.
Understanding Illumina’s Gross Margin Trend
Illumina’s cost of product revenue increased from $173.0 million in the third quarter of 2017 to $184.0 million in the third quarter of 2018.
Understanding Illumina’s Geographical Performance
For 2018 and 2019, Illumina is expected to generate revenues of $3.33 billion and $3.80 billion, respectively.
How Johnson & Johnson’s Medical Device Business Stands Now
Johnson & Johnson’s (JNJ) Medical Devices segment generated net revenues of $6.6 billion in the third quarter, reflecting ~0.2% YoY growth.
What Waters Corporation’s Valuation Trend Indicates
In September, of the 15 analysts covering Waters Corporation (WAT) stock, ten have given it “holds.”
A Look at Danaher’s Spin-Off of Its Dental Unit
In July, Danaher (DHR) announced that it would spin off its Dental segment into a separate public company.
Analyzing Perrigo’s Spin-Off of Its Rx Business
In this series, we’ll analyze major spin-offs in the healthcare sector by Perrigo (PRGO), Eli Lilly (LLY), Danaher (DHR), and Henry Schein.
A Performance Overview of Roche’s Diagnostics Division
In July, Roche received the CE Mark for its Accu-Chek Solo micropump system.
3M’s Stock Performance since Its 4Q17 Earnings
In a press release, 3M (MMM) said that it plans to announce its 1Q18 earnings on April 24, 2018, before the market opens.
Reading Dentsply Sirona’s Guidance for 2018
For fiscal 2018, the company expects its sales to be in the range of $4.2 billion–$4.25 billion.
Why Is Dentsply Sirona So Confident That It Can Gain Market Share?
Although Dentsply Sirona has given a disappointing performance recently, the company is still confident that it can gain a higher market share going forward.
Why Innovation Matters to Dentsply Sirona—Now More Than Ever
Dentsply Sirona has an industry-leading R&D budget with more than 600 scientists and engineers. The company invests $125 million per year on R&D.
Understanding Dentsply Sirona’s New Organizational Structure
In 4Q17, Dentsply Sirona (XRAY) started reporting its operations under two segments, after a shift to three segments in fiscal 3Q17.
Why Analysts Are Positive on W.R. Grace
In the past six months, the number of analysts covering W.R. Grace (GRA) has fallen from 14 to the present 11.
Why Is Wall Street Still Upbeat on Dentsply Sirona’s Growth Potential in 2018?
Dentsply Sirona is a leading dental technology, equipment, and consumables provider in the US. But it has been going through some tough times.
What Short Interest in Stanley Black & Decker Suggests
Data from February 28, 2018, shows that Stanley Black & Decker’s (SWK) short interest has fallen since the beginning of 2018.
Could Stanley Black & Decker Stock Bounce Back?
Stanley Black & Decker (SWK) stock has remained low since the beginning of 2018.
What’s the Competitive Landscape for Accelerate Diagnostics?
Accelerate Diagnostics (AXDX) currently competes with companies with automated microbiological testing products on the market like Becton Dickinson (BDX), bioMerieux, Danaher (DHR), Bruker (BRKR), Luminex (LMNX), and T2 Biosystems (TTOO).
What’s the Potential Market for Accelerate Diagnostics’ Products?
Accelerate Diagnostics’ (AXDX) pheno system utilizes genotypic and phenotypic technology to identify infectious pathogens and perform antibiotic susceptibility tests.
Behind Align Technology’s Key Growth Driver in 2017
In 3Q17, Align Technology’s (ALGN) Invisalign case volumes shipped to doctors in international markets rose 47.4% on a YoY basis and 6.8% sequentially.
Developments in Dentsply Sirona’s Digital Dentistry Portfolio
On September 20, 2017, Dentsply Sirona (XRAY) announced an enhancement to its Galileos Implant software.
Dentsply Sirona’s Newly Launched Cerec Zirconia Meso Block
In August 2017, Dentsply Sirona (XRAY) launched its Cerec Zirconia Meso Block for creating customized screw-retained crowns.
Dentsply Sirona’s Dental Sleep Medicine and a Recent Partnership
Dentsply Sirona (XRAY) and Zephyr Sleep Technologies have entered into a strategic partnership for the treatment of OSA (obstructive sleep apnea).
What Analysts Are Recommending for Dentsply Sirona
According to the recommendations of 15 brokerage firms, 60.0% (or nine) of them have rated Dentsply Sirona (XRAY) a “buy,” and 33.0% (or five) have rated it a “hold.”
What Do Analysts Recommend for Dentsply Sirona?
Based on the recommendations of 16 brokerage companies, around 63% (or ten) of the analysts provided a “buy” recommendation for Dentsply Sirona.
Discussing Dentsply Sirona’s Updated 2017 Guidance
Dentsply Sirona made a downward revision to its fiscal 2017 guidance during the company’s 2Q17 earnings results announcement on August 9, 2017.
Dentsply Sirona’s Technologies Segment Sales Declined in 2Q17
In 2Q17, Dentsply Sirona’s (XRAY) Technologies business contributed ~44% to the company’s total revenues and registered sales of ~$439 million.
Align Technology Focuses on International Market Strategy
International market strategy In 2Q17, Align Technology (ALGN) reported 85,400 Invisalign case shipments in international markets, which is YoY (year-over-year) growth of ~37.4% and sequential growth of ~13.6%. This growth was mainly attributed to new customers in the EMEA (Europe, the Middle East, and Africa) and Asia-Pacific markets. If Align Technology continues to demonstrate solid […]
Inside Align Technology’s Market Expansion Strategy
In 1Q17, Align Technology (ALGN) also witnessed a robust rise of around 45.2% in volumes of Invisalign sold in Asia-Pacific markets on a YoY basis.
Understanding Align Technology’s Growing Position in International Markets
In 1Q17, Align Technology (ALGN) witnessed an 11.4% sequential rise in the volume of Invisalign cases used by doctors in international markets.
These Are Align Technologies Key Demand Drivers in North America
In 1Q17, Align Technology (ALGN) has started selling its new product Invisalign Go in North America, which involves a few DSOs (dental service organizations).
Behind Align Technology’s North American Expectations for 2017
In 1Q17, Align Technology’s (ALGN) Invisalign sales volumes in North American markets rose YoY by 20.3% and QoQ by 8.3%.
Why Align Technology’s Orthodontics Is a Solid Growth Opportunity in 2017
Align Technology (ALGN) is a medical device provider focused on malocclusion or teeth misalignment condition.
Inside Align Technology’s Robust Revenue Growth Projection for 2017
For fiscal 2017, Align Technology (ALGN) expects its 2017 revenues to grow operationally in the range of 15%–25% YoY.
Align Technology versus Peers in June 2017: Analyst Recommendations
For 1Q17, Align Technology (ALGN) reported revenues close to $310.3 million, which represents YoY (year-over-year) growth of around 30.0%.
What Does Thermo Fisher Want in the Clinical Mass Spectrometry Business?
Thermo Fisher Scientific (TMO) is focused on strengthening its mass spectrometry business, which is part of its Analytical Instruments segment.
What Bio-Rad Laboratories Expects from Life Science
In 1Q17, Bio-Rad Laboratories’ (BIO) Life Science segment reported revenues of ~$174.3 million, which represents a YoY rise of ~5.1%.
Inside Bio-Rad Laboratories’ Profit Margin Expectations in 2017
On March 13, 2017, Bio-Rad Laboratories (BIO) announced that it expects to reach an EBITDA margin of around 20% by 2020.
Inside Bio-Rad Laboratories’ Robust Revenue Growth Projection for 2017
On March 13, 2017, Bio-Rad Laboratories (BIO) provided a long-term, currency-neutral revenue growth target of around 3%–5%.
Bio-Rad Laboratories on the Street: Analysts’ Recommendations in May
In 1Q17, Bio-Rad Laboratories (BIO) reported revenues of ~$500.1 million, which represented a YoY (year-over-year) rise of around 6.1%.
Dentsply Sirona’s New Growth Strategy to Accelerate Digital Dentistry Penetration
Dentsply Sirona is the largest dental equipment and solutions manufacturer in the United States. Digital dentistry is a megatrend in the market.
How Did Danaher’s Operating Segments Fare in 4Q16?
Currently, Danaher (DHR) reports its revenue under four operating segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Why Danaher Stock Rose after Its 4Q16 Results
Danaher Corporation (DHR) announced its 4Q16 and 2016 earnings results before the market opened on January 31, 2017. Let’s take a look.
A Look at Danaher’s 4Q16 Margin Estimates
In 4Q15, Danaher’s (DHR) adjusted EBITDA (earnings before interest, tax, depreciation, and amortization) was ~$1.4 billion, while its EBITDA margin was 23.3%.
Behind Danaher’s 4Q16 Revenue Estimates
Danaher (DHR) reported ~$5.9 billion in consolidated revenue in 4Q15. Analysts expect DHR to report $4.5 billion in 4Q16 revenue.
How Do Analysts Rate Danaher ahead of Its 4Q16 Results?
Of the 19 analysts covering Danaher, 15 had given the company “buy” ratings, four had given it “hold” ratings, and none had given it “sell” ratings as of January 12, 2017.
What Factors Could Drive Danaher Stock in 2017?
Danaher Corporation (DHR) will announce its 4Q16 earning results before the market opens on January 31, 2017. What should we expect?
Ecolab Declares a Dividend of $0.37 per Share
Price movement Ecolab (ECL) has a market cap of $35.4 billion. It rose 0.67% to close at $119.61 per share on December 8, 2016. The stock’s weekly, monthly, and year-to-date (or YTD) price movements were 0.95%, 5.3%, and 5.5%, respectively, on the same day. ECL is trading 3.0% above its 20-day moving average, 2.7% above […]
With Phenomenex, Danaher Has an Attractive Consumables Asset
On October 12, Danaher announced its an agreement to acquire Phenomenex, a privately held manufacturer of separation and purification consumables.
Why the T. Rowe Price Blue Chip Growth Fund Has Had a Rough 2016
TRBCX has had quite a poor run in 2016 so far. The fund places in the bottom three in the YTD period among the 12 funds in this review.
Inside the MFS Growth Fund Portfolio
Information technology, consumer discretionary, and healthcare sectors form the core of MFEGX, with a combined 73% of the fund’s net assets.
How Cepheid Fits Strategically into DHR’s Portfolio
The acquisition of Cepheid (CPHD) in the strategic sense is a gateway for Danaher (DHR) to breathe life into its limited molecular testing capabilities.
DHR to Reap $200 Million in Cost Synergies, Revenue through Buy
Danaher (DHR) says it has identified $100 million in cost synergies and another $100 million in revenues over the next five years.
What Made Cepheid Attractive to Danaher?
On September 6, 2016, Danaher (DHR) announced that it has entered into a definitive agreement to acquire Cepheid (CPHD) for $4 billion.